Beyond nutrition: lipids-based therapeutics from food and bioactive lipids

Abstract

Lipid based therapeutics represent a clinically influential segment of the global pharmaceutical market and illustrate how the Food as Medicine concept can be translated into rigorously validated drugs. Lovaza/Omacor is a defining example: originally derived from a supplement grade omega-3 mixture, it progressed through large cardiovascular outcome trials such as GISSI Prevenzione and ultimately achieved full medicinal status, becoming the most commercially successful omega-3 drug worldwide. This trajectory is not unique. Retinoids and prostaglandin analogues show that lipid derived or nutrient related molecules can evolve into major therapeutic classes once they are purified, standardized, and clinically tested. Across fatty acids, prostaglandins, and retinoids, successful agents share clear mechanisms of action, controllable pharmacokinetics, and robust outcome level evidence—exemplified by icosapent ethyl and bempedoic acid in cardiovascular prevention, prostacyclins in pulmonary arterial hypertension, and retinoids in dermatology. By contrast, many investigational lipid compounds fail due to mechanistic ambiguity, safety liabilities, chemical instability, or poor regulatory fit. Cross-class analysis shows that lipid drugs succeed when their inherent biological promiscuity is constrained through formulation, structural refinement, and targeted delivery. Looking ahead, progress is expected from intravenous omega-3 emulsions, stable specialized pro resolving mediator analogues, next generation retinoids, and precision lipid modulators designed to harness endogenous signalling with greater specificity.